Meropenem Fresenius Kabi

Meropenem, the active ingredient in Meropenem Fresenius Kabi, is a carbapenem antibiotic presented as a sterile intravenous solution for intravenous use. It treats severe bacterial infections in hospitalized patients.

GNH USA supplies Meropenem Fresenius Kabi as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections in the hospital setting.

Complicated intra‑abdominal infections: effective bacterial eradication in patients with intra‑abdominal sepsis. Complicated urinary tract infections: clears resistant uropathogens in complicated cases. Hospital‑acquired pneumonia: provides coverage against multidrug‑resistant organisms. Ventilator‑associated pneumonia: treats ventilator‑related lung infections. Septicemia: rapidly reduces bloodstream bacterial load. Other severe infections caused by susceptible bacteria: used when pathogens are known to be meropenem‑sensitive.

Common Side Effects: - Nausea or vomiting: gastrointestinal upset occurring in many patients. - Diarrhea: may be mild to moderate and self‑limiting. - Rash or pruritus: skin reactions ranging from mild erythema to urticaria. - Headache: transient headache reported during therapy. - Elevated liver enzymes: transient increases in ALT/AST. - Injection site phlebitis: irritation at the IV site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile‑associated diarrhea: may lead to colitis. - Renal toxicity: acute kidney injury in predisposed individuals. - Hematologic abnormalities: thrombocytopenia or neutropenia. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Meropenem should be used with caution in specific clinical situations.

Renal function: adjust dose in patients with impaired renal clearance. Allergy: avoid in individuals with known hypersensitivity to carbapenems or β‑lactams. Seizure risk: monitor patients with a history of seizures or CNS disorders. Pregnancy: consider only if the potential benefit outweighs the risk to the fetus. Drug interactions: review concomitant medications for possible interactions. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Valproic acid: meropenem reduces serum valproate levels, increasing seizure risk. - Probenecid: may increase meropenem plasma concentrations, raising toxicity potential. - Cytotoxic agents (e.g., cyclophosphamide): heightened neurotoxicity risk.

Moderate Interactions (Monitor Closely): - Loop diuretics: may exacerbate renal impairment. - Anticoagulants (warfarin): possible alteration of INR values. - Oral contraceptives: reduced efficacy, consider alternative contraception.